Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893562 | 0.78 | PPARG (0.42) | PPARGPTGDR2AGTR1AGTR2APEX1 | |
| SCHEMBL1889687 | 0.74 | PTGDR2 (0.39) | PPARGPTGDR2APEX1 | |
| SCHEMBL1885452 | 0.73 | TRPM8 (0.41) | PPARGPTGDR2KMT2A | |
| SCHEMBL1890982 | 0.71 | APEX1 (0.49) | PPARGPTGDR2AGTR1AGTR2APEX1 | |
| SCHEMBL1886847 | 0.70 | BRD4 (0.38) | BRD4KMT2A | |
| SCHEMBL1888097 | 0.68 | PPARG (0.38) | PPARGAGTR1AGTR2 | |
| SCHEMBL1889207 | 0.68 | SMN1; SMN2 (0.42) | PPARGPTGDR2KMT2A | |
| SCHEMBL1887901 | 0.68 | PPARG (0.39) | PPARGPTGDR2APEX1 | |
| SCHEMBL1892270 | 0.67 | LMNA (0.55) | PTGDR2F2 | |
| SCHEMBL8026444 | 0.67 | GLO1 (0.46) | BRD4GLO1AGTR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | PPARG 123/4885BRD4 954/4885PTGDR2 3/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | PPARG 123/4885BRD4 954/4885PTGDR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.